Cambrex Increases Flexible Manufacturing Capacity at Karlskoga, Sweden Facility

East Rutherford, NJ – July 1, 2020 – Cambrex, the leading small molecule company providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced that it is investing $3.6 million at its Karlskoga, Sweden facility to increase flexible drug substance manufacturing capacity. The work, which will convert a previously customer-dedicated manufacturing train, will include an additional production line at 6 m³ scale being added at the site. This will result in a 25 percent capacity increase at the facility.

Engineering work has already commenced at the facility and is expected to be completed by November 2020. The work involves modification of an existing 4 reactor configuration and the installation of new holding tanks and a 4 m2 Hastelloy Rosemund filter.

“We are seeing continued growth in commercial-scale API manufacturing, and an ongoing trend for customers favoring high-quality European and US partners, so we must ensure capacity is both flexible and available to be in a position to react quickly and effectively to customers’ changing requirements,” commented Bjarne Sandberg, Managing Director, Cambrex Karlskoga. “This investment, as with others made by Cambrex across our global network, is in line with the company strategy of ensuring that the assets we can offer customers allow for the most cost-effective and efficient manufacturing.”

Cambrex’s site in Karlskoga employs over 400 people and features a wide range of flexible manufacturing facilities, including 4 cGMP pilot plants and 5 full-scale commercial production units. In 2019, a new 600 m2 process and analytical development facility was added to the site, along with a 3,000 m2 logistics center.

About Cambrex

Cambrex is the leading small molecule company that provides drug substance, drug product, and analytical services across the entire drug lifecycle. The company provides customers with an end-to-end partnership for the research, development, and manufacture of small molecule therapeutics. With over 35 years’ experience and a growing team of over 2,100 experts servicing global clients from sites in North America and Europe, Cambrex is a trusted partner in branded and generic markets for API and dosage form development and manufacturing.

Cambrex offers a range of specialist drug substance technologies and capabilities, including biocatalysis, continuous flow, controlled substances, solid state science, material characterization, and highly potent APIs. In addition, Cambrex can support conventional dosage forms, including oral solids, semi-solids, and liquids, and has the expertise to manufacture specialist dosage forms such as modified-release, fixed-dose combination, pediatric, bi-layer tablets, stick packs, topicals, controlled substances, sterile and non-sterile ointments.

For more information, visit www.cambrex.com

Contact:Eli Cohen
Senior Director, Marketing and Communications
Tel: +447796 963 726
Email: eli.cohen@cambrex.com

 

 

Posted by Nicola Good
Tags